Why is Steris (STE) down 1.8% since last earnings report?

A month has gone by since the last earnings report for Steris. Shares have lost about 1.8% in that time frame, underperforming the S&P 500.

Will the recent negative trend continue leading up to its next earnings release, or is Steris due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers.

How have estimates been moving since then?

It turns out, estimates revision have trended downward during the past month.

VGM Scores

At this time, Steris has an average Growth Score of C, a grade with the same score on the momentum front. Following the exact same course, the stock was allocated a grade of C on the value side, putting it in the middle 20% for this investment strategy.

Overall, the stock has an aggregate VGM Score of C. If you aren't focused on one strategy, this score is the one you should be interested in.

Outlook

Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Notably, Steris has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.

Performance of an industry player

Steris is part of the Zacks Medical - Instruments industry. Over the past month, Pacific Biosciences of California , a stock from the same industry, has gained 11.3%. The company reported its results for the quarter ended March 2025 more than a month ago.

Pacific Biosciences reported revenues of $37.15 million in the last reported quarter, representing a year-over-year change of -4.3%. EPS of -$0.15 for the same period compares with -$0.26 a year ago.

Pacific Biosciences is expected to post a loss of $0.18 per share for the current quarter, representing a year-over-year change of +10%. Over the last 30 days, the Zacks Consensus Estimate has changed +1.4%.

Pacific Biosciences has a Zacks Rank #2 (Buy) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of D.

Want the latest recommendations from Zacks Investment Research? Download 7 Best Stocks for the Next 30 Days. Click to get this free report